Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GT Biopharma, Inc.GTBP · Entity 7878 | Director · CEO | February 01, 2019 | March 19, 2019 |
| MANNKIND CORPMNKD · Entity 4792 | Corp VP, CMO | August 10, 2017 | August 11, 2017 |
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | CHIEF DEVELOPMENT OFFICER | August 13, 2024 | August 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GT Biopharma, Inc.
Report date February 01, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 1,351,918 |
Reported balance
After 2019-02-01 transaction · row 1
1 source rowRow 1 · 2019-02-01 · Sale · Disposed 176,980 · Balance 1,351,918 F1: The disposal of the 176,980 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The disposal of the 176,980 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018.
MANNKIND CORP
Report date August 10, 2017 · Filed August 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock,$.01 par valueSEC Table I · non-derivative | Direct | 2,924 |
Reported balance
After 2017-08-10 transaction · row 1
1 source rowRow 1 · 2017-08-10 · Sale · Disposed 296 · Balance 2,924 F1: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units.
SOLENO THERAPEUTICS INC
Report date August 13, 2024 · Filed August 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.52 · Expires 2034-08-13 | Direct | 145,000 |
Reported balance
After 2024-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-13 · Grant · Acquired 145,000 · Balance 145,000 F1: One-fourth of the shares subject to the Option shall vest on August 12, 2025 and one forty-eighth of the shares subject to the Option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date.. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of the shares subject to the Option shall vest on August 12, 2025 and one forty-eighth of the shares subject to the Option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date..
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2024 Filed Aug 23, 2024 23:16 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 145,000 | $0.00 Strike: $49.52 | $0.00 |
DisclosureSEC source: 0001415889-24-022164 · form4-08232024_110801.xml · derivative · entry 1 Urbanski Raymond W. · CIK 0001653096 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2034-08-13 F1 · derivative.exercise_date: One-fourth of the shares subject to the Option shall vest on August 12, 2025 and one forty-eighth of the shares subject to the Option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date.. Read SEC document |
| February 01, 2019 Filed Mar 19, 2019 18:38 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | Salecommon stock | 176,980 | $0.00 | $176.98 |
DisclosureSEC source: 0000939798-19-000008 · primary_doc.xml · nonDerivative · entry 1 Urbanski Raymond W. · CIK 0001653096 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,351,918 F1 · shares: The disposal of the 176,980 shares was made to satisfy obligations pursuant to the terms of a Stock Pledge Agreement signed on August 1, 2018. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 22:17 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock,$.01 par value | 296 | $1.15 | $340.40 |
DisclosureSEC source: 0001209191-17-048662 · doc4.xml · nonDerivative · entry 1 Urbanski Raymond W. · CIK 0001653096 · Corp VP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924 F1 · shares: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.